201402-18-8

Upstream product

• 2969-81-5 Ethyl 4-bromobutyrate 
• 16874-12-7 Tyr(tBu) 
• 202259-31-2 (2S)-2-(1-Adamantyl-methyloxycarbonylamino)-3-(4-(3-guanidinocarbonyl-propyloxy)phenyl)propionic Acid 
• 6163-66-2 2,2'-oxybis(2-methyl-propane) 

Downstream Products

• 372136-52-2 (1,1-dimethylethyl) N-(2-benzoxazolyl)-O-(4-ethoxy-4-oxobutyl)-L-tyrosinate 
• 372136-61-3 (1,1-dimethylethyl) N-(5-bromo-7-fluoro-2-benzoxazolyl)-O-[4-oxo-4-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]butyl]-L-tyrosinate 
• 372136-50-0 (1,1-dimethylethyl) O-(4-ethoxy-4-oxobutyl)-N-[1-(phenylmethyl)-1H-tetrazol-5-yl]-L-tyrosinate 
• 372136-57-7 (1,1-dimethylethyl) N-[[(4-bromophenyl)amino]thioxomethyl]-O-(4-ethoxy-4-oxo-butyl)-L-tyrosinate 

Relevant academic research and scientific papers

ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR

The invention concerns vitronectin receptor antagonist compounds of formula (I): R1—Y-A-B-D-E-F-G wherein R1, Y, A, B, D, E, F, and G are as defined in the description, their physiologically acceptable salts and their prodrugs, metho

Cycloalkyl derivatives as inhibitors of bone resporption and vitronectin receptor antagonists

There are described cycloalkyl derivatives of the formula (I) R1—Y—A—B—D—E—F—G??(I) in which R1, Y, A, B, D, E, F and G have the meaning indicated herein, their preparation and their use as medicaments. The compounds according to the